Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. 2015

Y G Yang, and M Zhang, and N Jiang, and L X Song, and X T Xu, and X H Di, and L Xu, and J Xu, and G T Zhao
Department of Pharmacology, General Hospital of Beijing Military Command, Beijing, China.

We aimed to evaluate the bioequivalence of clopidogrel in healthy Chinese volunteers after administration of a single oral dose. We administered a single oral dose of 75 mg clopidogrel (test and reference) to 32 healthy Chinese volunteers according to an open, randomized, crossover design. The concentration of clopidogrel acid (carboxylic metabolite of clopidogrel) in the plasma was determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Bioequivalence of the test and reference preparations were calculated using analysis of variance and one-sided t-test by using the DAS 2.0 software. The pharmacokinetic parameters of the test and reference preparations were as follows: peak plasma concentration (Cmax), 1351.101 ± 654.955 ng/mL and 1184.652 ± 607.713 ng/mL; area under the curve, 2642.017 ± 1093.848 ng·h/mL and 2780.666 ± 1283.100 ng·h/mL; and time to reach Cmax (Tmax), 0.789 ± 0.318 h and 0.953 ± 0.633 h, respectively. The relative bioavailability of the formulation was 101.7 ± 35.3%, which indicated that the test preparation was bioequivalent to the reference drug.

UI MeSH Term Description Entries
D002853 Chromatography, Liquid Chromatographic techniques in which the mobile phase is a liquid. Liquid Chromatography
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077144 Clopidogrel A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION. Clopidogrel Besilate,Clopidogrel Besylate,Clopidogrel Bisulfate,Clopidogrel Hydrochloride,Clopidogrel Napadisilate,Clopidogrel Sandoz,Clopidogrel, (+)(S)-isomer,Clopidogrel-Mepha,Iscover,PCR 4099,PCR-4099,Plavix,SC 25989C,SC 25990C,SR 25989,Clopidogrel Mepha
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013607 Tablets Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed) Tablet
D013988 Ticlopidine An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES. 53-32C,Ticlid,Ticlodix,Ticlodone,Ticlopidine Hydrochloride,53 32C,5332C,Hydrochloride, Ticlopidine
D015203 Reproducibility of Results The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results. Reliability and Validity,Reliability of Result,Reproducibility Of Result,Reproducibility of Finding,Validity of Result,Validity of Results,Face Validity,Reliability (Epidemiology),Reliability of Results,Reproducibility of Findings,Test-Retest Reliability,Validity (Epidemiology),Finding Reproducibilities,Finding Reproducibility,Of Result, Reproducibility,Of Results, Reproducibility,Reliabilities, Test-Retest,Reliability, Test-Retest,Result Reliabilities,Result Reliability,Result Validities,Result Validity,Result, Reproducibility Of,Results, Reproducibility Of,Test Retest Reliability,Validity and Reliability,Validity, Face
D016903 Drug Monitoring The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically. Monitoring, Drug,Therapeutic Drug Monitoring,Drug Monitoring, Therapeutic,Monitoring, Therapeutic Drug

Related Publications

Y G Yang, and M Zhang, and N Jiang, and L X Song, and X T Xu, and X H Di, and L Xu, and J Xu, and G T Zhao
December 2009, International journal of clinical pharmacology and therapeutics,
Y G Yang, and M Zhang, and N Jiang, and L X Song, and X T Xu, and X H Di, and L Xu, and J Xu, and G T Zhao
December 2015, Rheumatology and therapy,
Y G Yang, and M Zhang, and N Jiang, and L X Song, and X T Xu, and X H Di, and L Xu, and J Xu, and G T Zhao
March 2012, Zhonghua xin xue guan bing za zhi,
Y G Yang, and M Zhang, and N Jiang, and L X Song, and X T Xu, and X H Di, and L Xu, and J Xu, and G T Zhao
November 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
Y G Yang, and M Zhang, and N Jiang, and L X Song, and X T Xu, and X H Di, and L Xu, and J Xu, and G T Zhao
January 2024, Clinical pharmacology in drug development,
Y G Yang, and M Zhang, and N Jiang, and L X Song, and X T Xu, and X H Di, and L Xu, and J Xu, and G T Zhao
December 2023, Clinical pharmacology in drug development,
Y G Yang, and M Zhang, and N Jiang, and L X Song, and X T Xu, and X H Di, and L Xu, and J Xu, and G T Zhao
March 2013, Pakistan journal of pharmaceutical sciences,
Y G Yang, and M Zhang, and N Jiang, and L X Song, and X T Xu, and X H Di, and L Xu, and J Xu, and G T Zhao
January 2015, Therapie,
Y G Yang, and M Zhang, and N Jiang, and L X Song, and X T Xu, and X H Di, and L Xu, and J Xu, and G T Zhao
September 2012, Die Pharmazie,
Y G Yang, and M Zhang, and N Jiang, and L X Song, and X T Xu, and X H Di, and L Xu, and J Xu, and G T Zhao
September 2010, AAPS PharmSciTech,
Copied contents to your clipboard!